22
Participants
Start Date
August 31, 2011
Primary Completion Date
August 31, 2014
Study Completion Date
July 31, 2015
sphingosine kinase-2 inhibitor ABC294640
Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
Medical University of South Carolina, Charleston
Collaborators (1)
Apogee Biotechnology Corporation
INDUSTRY
Medical University of South Carolina
OTHER
FDA Office of Orphan Products Development
FED
National Cancer Institute (NCI)
NIH
RedHill Biopharma Limited
INDUSTRY